Skip to content

Association of obstructive sleep apnea with metabolic abnormalities in women with polycystic ovary syndrome: a cross-sectional study

Association of obstructive sleep apnea with metabolic abnormalities in women with polycystic ovary syndrome: a cross-sectional study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000035303
Enrollment
Unknown
Registered
2020-08-07
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome

Interventions

Subjects with OSA in PCOS patients (AHI=5 times/hour):Nil
Subejects without OSA in PCOS patients (AHI<5 times per hour):Nil

Sponsors

Union Hospital affiliated to Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria of Rotterdam in 2003: (1) Patients with rare ovulation or even no ovulation; (2) The clinical symptoms or biochemical manifestations of the patient showed hyperandrogenemia; (3) Color ultrasound of the abdomen showed polycystic ovary changes (vaginal color ultrasound showed that one or both ovaries contained more than 12 follicles of 2-9mm); If two of the three criteria are met, a diagnosis can be made. 2. Age: 18-45 years old women of childbearing age. 3. Did not receive any oral contraceptives, other forms of hormonal contraception or fertility treatment for at least 3 months, and did not receive progesterone treatment for at least 1 month prior to study participation. 4. Never received any cholesterol-lowering drug, antihypertensive drug, insulin sensitizer, metformin or any other diabetes medication. 5. Never received treatment for sleep apnea.

Exclusion criteria

Exclusion criteria: 1. Smokers. 2. Pregnant and lactating women. 3. People with neurological or mental illness. 4. Patients with thyroid diseases and hyperprolactinemia. 5. Those who have undergone ovarian or uterine surgery. 6. Patients with congenital adrenal hyperplasia, Cushing's syndrome, androgen secreting tumors.

Design outcomes

Primary

MeasureTime frame
Sex hormone test;blood lipid level;blood glucose level;fasting insulin level;polysomnogram;

Countries

China

Contacts

Public ContactLiuYi

Union Hospital affiliated to Huazhong University of Science and Technology

liqun94@163.com+86 13971038710

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026